Cyclic Peptide Antiviral Agents for Dual-Site gp120 Entry Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HIV-1 entry inhibitors suffer from weak potency and toxicity issues, and there is a need for novel compounds that can treat or prevent HIV-1 infection and cause virus lysis without cellular involvement.
Innovation Solution
Development of cyclic peptide compounds that target the gp120 protein, inhibiting both CD4 and co-receptor binding sites, and conjugation with gold nanoparticles to enhance antiviral activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HIV-1 entry inhibitors are used, then viral entry can be blocked, but potency is weak and toxicity issues occur
Solution Approach 1:
The patent modifies the chemical structure of existing entry inhibitors by introducing cyclic peptide compounds with specific amino acid sequences and modifications (e.g., N-methylated amino acids, cyclic constraints) to optimize binding affinity for gp120 while reducing off-target effects and toxicity. This structural parameter optimization resolves the contradiction between efficacy and toxicity.
Solution Approach 2:
The invention develops hybrid compounds combining peptide motifs with small molecule pharmacophores, creating composite structures that leverage the specificity of peptides and the potency of small molecules. These composite entry inhibitors achieve high antiviral efficacy with reduced toxicity compared to conventional single-class inhibitors.
2Reliability
If conventional entry inhibitors are used, then CD4 or co-receptor binding can be blocked, but potency remains weak
Solution Approach 1:
The patent segments the gp120 binding interface into multiple interaction zones and designs cyclic peptide compounds with distributed pharmacophores that simultaneously engage multiple regions (CD4 binding site, co-receptor binding site, and adjacent epitopes). This multi-point attachment strategy dramatically enhances binding affinity and potency compared to single-site inhibitors.
Solution Approach 2:
The invention employs nested cyclic structures where smaller cyclic motifs are incorporated within larger cyclic frameworks, creating multi-layered conformational constraints that stabilize high-affinity binding conformations. This nested architecture enables potent inhibition through cooperative binding interactions.
3Reliability
If peptide-based inhibitors are used, then binding affinity can be enhanced, but metabolic stability and lifetime are reduced
Solution Approach 1:
The patent systematically modifies peptide parameters including N-methylation of amino acids, introduction of non-natural amino acids with enhanced stability, and cyclic constraints to reduce susceptibility to proteolytic degradation. These parameter changes maintain high binding affinity while dramatically improving metabolic stability and in vivo lifetime.
Solution Approach 2:
The invention replaces labile natural amino acid residues with more stable synthetic analogs that resist enzymatic degradation, effectively extending the functional lifetime of the peptide inhibitor without compromising its binding affinity or mechanism of action.
Data Source
AI summary
The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.